Compare CATX & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CATX | EOLS |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.0M | 454.4M |
| IPO Year | 2018 | 2018 |
| Metric | CATX | EOLS |
|---|---|---|
| Price | $2.97 | $5.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $12.11 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 2.6M | 776.9K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | N/A | $17.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $1.96 | $3.86 |
| 52 Week High | $6.16 | $10.20 |
| Indicator | CATX | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.91 | 36.03 |
| Support Level | $2.86 | $4.02 |
| Resistance Level | $4.27 | $7.16 |
| Average True Range (ATR) | 0.23 | 0.35 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 16.15 | 18.12 |
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.